Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMB305 in NY-ESO-1 Expressing Cancers
NCT02387125Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- Feb 2015
- Primary completion
- Mar 2019
- Modality
- Vaccine mRNA, mRNA Vaccines, Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of CMB305 in melanoma, sarcoma, ovarian cancer and 1 more (6 arms), sponsored by Merck & Co. Primary endpoint: Nature, frequency and severity of adverse events and laboratory abnormalities up to 5 years. Started Feb 2015; status: terminated.
02
Drugs
CMB305
03
Conditions
melanomasarcomaovarian cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02387125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02387125.